Modulating conjunctival wound healing

Advances in molecular and cell biology have led to an expansion in our know ledge and understanding of the processes involved in wound healing. We revi ew existing and potential therapies modulating the conjunctival scarring re sponse, with particular reference to glaucoma filtration surgery. We discus s how the refinement of present antimetabolite regimens can minimise compli cations and improve surgical results, and advocate their use in carefully s elected patient groups. Perhaps the most promising approach is targeting bi ological molecules. Hence, use of fully human neutralising monoclonal antib odies to the growth factor TGF beta has potential as a useful strategy for modifying conjunctival scarring. Combination therapies may also afford an i mproved therapeutic index. It is hoped that future therapies can offer safe r, more specific, focal and titratable treatment, with far-reaching clinica l applications.